BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, March 19, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 28, 2007

View Archived Issues

Phase I/II study of Oncohist in leukemia progresses

Read More

Activity seen with SNS-595 in acute leukemia patients

Read More

Preliminary phase I results with AT-9283 in hematological malignancies encouraging

Read More

Bupropion ameliorates methamphetamine dependence in some patients

Read More

New agents for musculoskeletal and connective tissue disorders claimed in recent patents

Read More

Novel therapeutic agents for Alzheimer's disease disclosed in recent patent literature

Read More

Update on Intra-Cellular Therapies' ITI-007/ITI-722 for schizophrenia and SMI

Read More

New agents for treating hematologic disorders reported in recent patents

Read More

Tissue-specific FAK gene deletion blocks mammary tumor progression

Read More

Ono enters license agreement with Nissan Chemical for new drug for thrombocytopenia

Read More

Novavax reports positive interim results from phase I/IIa trial of H5N1 vaccine

Read More

Nektar and Baxter expand agreement to develop PEGylated therapeutics for hemophilia

Read More

CFFT selects Triolex as drug candidate for lung inflammation linked with cystic fibrosis

Read More

Intercell submits BLA with FDA for Japanese encephalitis virus vaccine

Read More

Phase III clinical trial of Genitope's MyVax fails to meet primary endpoint

Read More

Peregrine gives update on its three lead clinical programs for bavituximab and Cotara

Read More

Actelion initiates RESTORA 1 phase III study of almorexant for primary insomnia

Read More

Corcept commences phase III Corlux trial for endogenous Cushing's syndrome

Read More

Pfizer receives FDA approvable letter for dalbavancin

Read More

GlaxoSmithKline and Santaris enter RNA antagonist alliance

Read More

Taxus Liberte drug-eluting stent receives CE mark for use in patients with diabetes

Read More

GlobeImmune initiates phase II GI-5005 trial in patients with chronic hepatitis C

Read More

ExonHit obtains approval to start phase II EHT-0202 trial in Alzheimer's disease

Read More

Galapagos enters strategic alliances with GlaxoSmithKline and Lilly

Read More

R-1507 antibody enters phase II sarcoma study

Read More

Phase II IPI-504 trial initiated in patients with non-small cell lung cancer

Read More

Conatus initiates phase II clinical trial for the treatment of hepatitis

Read More

VGX files IND for VGX-1027, a small molecule with antiinflammatory activity

Read More

Bazedoxifene receives second FDA approvable letter for prevention of osteoporosis

Read More

Noven reports FDA tentative approval of Stavzor valproic acid delayed release capsules

Read More

Popular Stories

  • Today's news in brief

    BioWorld

    BioWorld briefs for March 19, 2026.

  • Art concept for targeting the brain

    Precision psychiatry beyond, or before, biomarkers

    BioWorld
    There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
  • Illustration of a motor neuron

    Keros reports beneficial effects of RKER-065 in ALS model

    BioWorld Science
    Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 17, 2026
  • First-in-class POLG activator restores mtDNA across mutations

    BioWorld Science
    Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing